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Aims Few studies have investigated the association between implantable cardioverter defibrillators (ICDs) and lead
advisory notifications and patient-reported outcomes (PROs). We examined (i) whether the mode used to
inform patients about a device advisory is associated with PROs, and (ii) whether patients with a lead subject to a
device advisory report poorer PROs than non-advisory controls.
Methods
and results
Patients (n ¼ 207) implanted with an ICD at Aarhus University Hospital, Denmark, with a Sprint Fidelis lead subject
to an advisory and a non-advisory control group (n ¼ 510), completed a set of standardized PRO measures. A Bon-
ferroni correction was applied to all statistical PRO comparisons to adjust for multiple comparisons, with a P-value of
0.0038 (0.05/13 PROs) indicating statistical significance. Device advisory patients did not differ significantly on PROs
according to mode of notification (all P-values .0.0038). They also did not differ significantly from controls on mean
scores of depression, anxiety, device acceptance, and health status (all P. 0.0038). Differences were only found on
ICD concerns (P, 0.0001) and on mental health status (P ¼ 0.003), with advisory patients reporting fewer ICD con-
cerns and a better mental health status than non-advisory controls.
Conclusions The mode used to inform ICD patients about the advisory was not associated with PROs, nor was the overall
well-being of device advisory patients impaired compared to non-advisory controls. These results indicate that
ICD patients are generally able to cope with a device advisory.
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Introduction
Implantable cardioverter defibrillator (ICD) therapy is the first-line
treatment for the primary and secondary prevention of sudden
cardiac death.1 Despite its medical benefits, ICD therapy is associ-
ated with a potential for procedure-related (e.g. infection and
bleeding) and device-related (e.g. inappropriate shocks and lead
dysfunction) complications.2,3 Device-related complications, such
as device dysfunction and lead fracture, have increased in the last
decade, although it is not a new phenomenon.4 However,
guidelines are now in place from the Food and Drug Adminis-
tration and the Heart Rhythm Society on device performance
and also on how device advisory notifications should be communi-
cated to patients.5
Device advisories may have an adverse influence on patient-
reported outcomes (PROs) such as well-being and quality of life.
As voiced in an editorial published in 2008 related to the Sprint
Fidelis advisory, there is an urgent need to examine the influence
of advisory notifications on patient well-being both with respect
to the impact of the advisory itself and with respect to how to
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communicate the risk to patients.6 A true estimation of the impact
of advisories on patients may serve to counterbalance the associ-
ated negative publicity in the press, which has led to patients
turning down this potentially life-saving treatment, as reported in
the USA.7
Few studies have examined the impact of device advisory notifi-
cations on patients, as assessed with PROs. In a recent viewpoint,8
we identified six studies, with sample sizes ranging from 31 to 86
patients with hardware subject to a Class I or a Class II advi-
sory.9–14 The evidence for a psychological impact of device advi-
sory notifications is mixed, as shown in an update of the
literature as presented in Table 1. Little is also known about the
most appropriate way of communicating the risk associated with
an advisory to patients and whether different modes may have a
differential influence on PROs.6
In the current study, we examined (i) whether the mode used to
inform patients about the Sprint Fidelis device advisory (i.e. inform-
ing patients by letter calling them in for an urgent clinical follow-up
visit vs. informing them ad hoc during a routine clinical visit) is
associated with mean scores on PROs, and (ii) whether patients
with a device advisory notification report poorer PROs than non-
advisory patients, assessed with both disease-specific and generic
measures.
Methods
Patients and study design
Patients (n ¼ 207; response rate 87%) implanted with an ICD between
1993 and 2009 at Aarhus University Hospital (Skejby), Denmark, and
with a lead (6931 or 6949) subject to the Medtronic Sprint Fidelis
ICD lead advisory completed a set of standardized and validated
PROs between September and October 2009. The Sprint Fidelis
ICD lead advisory was issued due to potential lead fracture that
could lead to not only unnecessary (inappropriate) shocks but also
failure to deliver life-saving defibrillatory shocks. Lead Integrity
AlertTM (LIA; Medtronic, Minneapolis, MN, USA) software was made
available for download to the device which would alert patients of
potential lead failure. In Denmark, the Sprint Fidelis lead advisory
was issued on 15 October 2007. All of our patients were informed
about the LIA software and the rationale at the time of downloading
it to their device.
Patients were informed about the advisory in one of the following
two ways: (i) by letter, in December 2008, calling patients in for an
urgent clinical follow-up visit, and (ii) ad hoc during a routine clinical
visit. Hence, for patients in group (i) the time interval between the
device advisory notification and completing the questionnaires was
9 months, whereas for those in group (ii) the interval was variable.
Both groups had the LIA software downloaded to their device
during the clinical follow-up visit.
A control group of patients (n ¼ 510), implanted with an ICD
between 1991 and 2006 at our institution but whose hardware
was not under advisory, had completed the same questionnaires
for a previous study (response rate 84%).17,18 For the majority of
the control patients (i.e. 95%), the main indication for ICD was sec-
ondary prevention, as primary prevention was not generally
implemented in Denmark before 2007. Both advisory and control
patients had to be ≥18 years of age to be eligible to participate.
For both groups, if the questionnaire was not returned within
2 weeks, a reminder was sent by post including a duplicate
questionnaire. The study was conducted according to the Declara-
tion of Helsinki.
Measures
Demographic and clinical variables
Information on demographic and clinical variables was obtained
from the Danish ICD Register (www.pacemaker.dk) or from purpose-
designed questions in the questionnaire.
Patient-reported outcomes
Symptoms of anxiety and depression
We used the 14-item Hospital Anxiety and Depression Scale (HADS)
to assess symptoms of anxiety and depression.19 Items are answered
on a 4-point Likert scale from 0 to 3 (score range 0–21), with
seven items contributing to the anxiety and depression subscales. A
high score on the HADS indicates more symptoms of anxiety and
depression. A cut-off score ≥ 8 for both subscales represents prob-
able clinical levels of anxiety and depression.20 The HADS is a valid
and reliable instrument that has been used across the world in
cardiac and non-cardiac populations,20 and that is not prone to
confounding by symptoms of somatic disease.21
Device-related concerns
The Implantable Cardioverter Defibrillator Patient Concerns
Questionnaire (ICDC) is an eight-item self-report measure tapping
into concerns about the ICD giving a shock (e.g. ‘I am worried about
my ICD firing’).22,23 Items are rated on a 5-point Likert scale from 0
(not at all) to 4 (very much so), with a higher score indicating a
higher level of device-related concerns (score range 0–32). The
internal consistency of the eight-item ICDC is good, with Cronbach’s
a ¼ 0.91.23 Previously, we have shown that high levels of
pre-implantation ICD concerns predict mortality in ICD patients.24
Device acceptance
Device acceptance was assessed with the 18-item Florida Patient
Acceptance Survey (FPAS).25 Items (e.g. ‘When I think about the
device, I avoid doing things that I enjoy’ and ‘I feel less attractive
because of my device’) are rated on a 5-point Likert scale from 1
(strongly disagree) to 5 (strongly agree). Of all items, 15 contribute
to a total score, while the remaining 3 items are filler items. A high
score indicates better acceptance. The convergent, divergent, and
discriminant validity of the FPAS are good, and the scale has been
shown to be internally consistent, as indicated by Cronbach’s
a ¼ 0.83 for the total scale. Previously, we validated the FPAS in
Danish ICD patients, with this specific language version indicating
good validity and reliability.26
Health status
We used both a disease-specific and generic measure of health status.
The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a
disease-specific measure, comprising 21 items.27 Items are answered
on a 6-point Likert scale from 0 (no) to 5 (very much). The total
score ranges from 0 to 105, with a higher score indicating poor
health status. The measure is psychometrically sound, with good
internal consistency as measured by Cronbach’s a ¼ 0.91–0.96 for
the total scale. The Short Form Health Survey (SF-36) is a generic
measure of health status, comprising 36 items that contribute to
eight domains:28,29 role physical functioning, role emotional function-
ing, physical functioning, mental health, vitality, social functioning,
bodily pain, and general health. Scale scores range from 0 to 100,
with a higher score indicating better functioning. The scale has good
reliability with Cronbach’s a ¼ 0.65–0.96 for all subscales.28
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Table 1 Overview of studies on the impact of device advisories on patient-reported outcomes*
Authors Origin of study Advisory n Response rate Study design Time between
advisory and
assessment
Endpointa Impact of device advisory
Birnie et al. (2009)14 Canada Class II advisory
(Medtronic)
86 advisory
patients; 94
controls
70.5% patients; 70.1%
controls
Case–control .24 months Device
acceptance2
No significant impact
van den Broek et al.
(2006)9
The Netherlands Class II advisory
(Medtronic)
33 advisory patients 90% Prospective; 14
+ 4 months
follow-up
,2 monthsb Anxiety1 Increase in the number of anxious
patients from 6.1%
pre-compared to 24.2%
post-advisory
Cuculi et al. (2006)13 Switzerland Class I advisory
(Guidant)
30 advisory
patients; 25
controls
Not reported Case–control ,1 month Distress1 No significant impact; 3 distress
measures were significantly
higher in the controls
Gibson et al. (2008)12 USA Class I advisory: 13/31
(42%) (Guidant)
31 advisory
patients; 50
controls
89% Case–control ,1 to .4 months Distress1; QoL1 No significant impact
Heatherly et al.
(2011)15
USA Class I advisory
(Medtronic)
158 advisory
patients; 255
controls
Not reported Case–control 14–22 months ICD concerns2 More ICD concerns in recalled
group (primarily due to shocks)
Keren et al. (2011)16 Canada Class II advisory
(Medtronic)
24 advisory lead
fracture; 249
advisory no
fracture; 143
controls
92% advisory lead
fracture; 74%
advisory no
fracture; 62%
controls
Case–control 13 months Anxiety1,2;
depression1;
device
acceptance2
No difference in distress between
no fracture and controls; more
distress in advisory fracture
patients due to inappropriate
shocks
Sneed et al. (1994)10 USA Class II advisory
(Guidant)
31 advisory
patients; 21
caregivers
100% Prospective,
case–control;
1-month
follow-up
1–3 months Distress2;
uncertainty2;
confidence in
device2
Patient and caregiver confidence
decreased; anxiety increased in
patients and confusion in
caregivers over time
Undavia et al. (2008)11 USA Class I advisory: 43/61
(70%) (not
mentioned)
61 advisory
patients; 43
controls
90% Case–control 7.6+1.6 months Anxiety1;
depression1;
QoL2
No significant impact
*Adapted from Pedersen et al.8
a‘Generic measure’ and ‘disease-specific measure’ are indicated by superscript numbers 1 and 2, respectively.
bConveyed via personal communication with the author.
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Statistical analyses
The three patient groups, that is, device advisory group (i) patients
who were informed by letter urging them to come in for a clinical
follow-up visit, device advisory group (ii) patients who were informed
ad hoc during a clinical follow-up visit, and control patients without a
device or leads subject to an advisory notification, were compared
on baseline characteristics using analysis of variance with a post-hoc
Bonferroni correction (if applicable) for continuous variables and
the x2 test for nominal variables. Student’s t-test for independent
samples was used to compare the two device advisory groups on
PROs, and the device advisory groups (irrespective of how information
was given about the advisory) with the control group on PROs. Due to
multiple comparisons that increase the chance of finding a statistically
significant result and to prevent making a Type I error (also known as a
false positive), we used a Bonferrroni correction for these analyses.
Accordingly, given that we had 13 PROs, we divided the standard
P value of 0.05 by 13, using a P value of 0.0038 to indicate statistical
significance for the interpretation of these results. However, for all
results (both in the text and in the figures), the exact P value for
each comparison is also reported. All analyses were performed using
SPSS 17.1 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics
Baseline characteristics stratified by advisory groups (i) and (ii) vs.
no advisory (control group) are displayed in Table 2. The groups
did not differ systematically on baseline characteristics, except
that advisory group (i) patients were more likely to have a
cardiac synchronization therapy with defibrillation (CRT-D)
device than advisory group (ii) patients and controls, and advisory
group (ii) patients were more likely to be prescribed b-blockers
than advisory group (i) patients and controls. Time since first
ICD implant was longer for controls than for advisory group (i)
and (ii) patients.
Patient-reported outcomes in device
advisory patients stratified by mode
of notification
No statistically significant differences were found on psychological
distress (Figure 1A) and health status (Figure 1B) between group (i)
patients who were notified about the device advisory by letter
calling them in for an urgent clinical follow-up visit and group (ii)
patients who were informed ad hoc during a routine clinical
follow-up visit, with all P values .0.0038 which was chosen to
indicate statistical significance.
Patient-reported outcomes stratified
by device advisory vs. control patients
Given that we found no statistically significant differences on PROs
between the two advisory groups stratified by mode of notifica-
tion, we merged groups (i) and (ii) and compared device advisory
patients with a non-advisory control group to examine potential
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Baseline characteristics stratified by device advisory vs. no advisorya
Characteristics Device advisory (i) (n5 74)b Device advisory (ii) (n5 133)c Controls (n 5 510) P
Demographic
Women 8 (10.8) 20 (15.0) 92 (18.0) 0.26
Age, mean+ SD (years) 63.2+13.2 61.6+14.7 64.0+13.1 0.18
Partner/married 58 (78.4) 102 (77.1) 393 (77.5) 0.94
Clinical
CRT-D 22 (30.1) 30 (22.6) 92 (18.0) 0.04
Comorbidity 15 (20.8) 29 (22.3) 116 (23.0) 0.92
Ischaemic heart disease 49 (70.0) 81 (67.5) 327 (70.6) 0.80
Smoking 13 (17.6) 26 (19.8) 119 (23.8) 0.36
Time since first ICD implant (years) 2.0+1.1 2.2+1.5 5.3+3.2 ,0.0001d
Medication
Amiodarone 10 (15.4) 34 (27.0) 123 (24.4) 0.19
b-Blockers 54 (83.1) 116 (92.1) 412 (82.4) 0.03
Diuretics 28 (43.1) 54 (42.9) 236 (46.9) 0.64
Thiazide diuretics 10 (15.4) 12 (9.5) 46 (9.3) 0.30
ACE-inhibitors 52 (80.0) 98 (77.8) 345 (69.8) 0.07
ARBs 13 (20.0) 37 (29.4) 156 (31.1) 0.18
Digoxin 15 (23.1) 23 (18.3) 84 (16.7) 0.43
Psychotropic medication 11 (16.9) 9 (7.2) 67 (14.1) 0.08
aResults are presented as n (%), unless otherwise indicated.
bDevice advisory (i) patients were notified of the device advisory by letter, in December 2008, calling them in for an urgent clinical follow-up visit.
cDevice advisory (ii) patients were notified ad hoc during a routine clinical visit.
dGroup differences were significant between controls and device advisory (i) patients and between controls and device advisory (ii) patients (post-hoc Bonferroni P, 0.0001),
but not between device advisory (i) and device advisory (ii) patients (post-hoc Bonferroni P ¼ 1.00).
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differences in PROs. There were no statistically significant differ-
ences between advisory and non-advisory patients on symptoms
of depression and anxiety, while advisory patients reported less
ICD concerns than non-advisory controls (5.12+6.04 vs.
7.67+8.28; P, 0.0001) (Figure 2A). As for device acceptance
and disease-specific and generic health status, there was only
one difference between groups, with advisory patients reporting
better mental health status than non advisory controls (82.46+
17.73 vs. 77.90+19.10; P ¼ 0.003) (Figure 2B).
Discussion
Device advisories may be unnerving to patients and may reduce
patient confidence in their device. For this reason, it is important
to examine the impact of device advisories on patient well-being
and device acceptance both with respect to the impact of the advi-
sory itself and with respect to how best to communicate the risk
to patients.6 In the current study, we examined the association
between mode of informing patients about the Sprint Fidelis lead
advisory and PROs and the association between having an ICD
lead subject to an advisory vs. no advisory and PROs, as assessed
with a broad range of PROs, including both disease-specific and
generic measures tapping into patient distress, health status,
device concerns, and device acceptance.
The mode used to inform ICD patients about the device advi-
sory—that is calling patients in for an urgent clinical follow-up
visit vs. informing patients ad hoc during a routine clinical visit—
was not associated with psychological well-being and health
status in our patient cohort, nor was the well-being and health
status of device advisory patients impaired compared to patients
without an advisory notice. In fact, non-advisory controls reported
more ICD concerns and poorer mental health status than advisory
patients, which is consistent with the findings of a previous study.13
De
pre
ssi
on
 (H
AD
S-D
)
An
xie
ty 
(HA
DS
-A)
ICD
 co
nce
rns
 (IC
DC
)
0
2
4
6
8
10
12
14
16 Device advisory (letter)
Device advisory (ad-hoc)
p=0.98
p=0.51
p=0.035
All comparisons were non-significant with a Bonferroni correction (all ps > .0038)
M
ea
n 
sc
or
e
De
vic
e a
cce
pta
nc
e (F
PA
S)
Dis
ea
se
-sp
ec
ific
 Qo
L (M
LW
HQ
)
Ph
ysi
ca
l F
un
ctio
nin
g (S
F-3
6)
So
cia
l F
un
ctio
nin
g (S
F-3
6)
Ro
le 
Ph
ysi
ca
l F
un
ctio
nin
g (S
F-3
6)
Ro
le 
Em
oti
on
al 
Fu
nc
tio
nin
g (S
F-3
6)
Me
nta
l H
ea
lth
 (SF
-36
)
Vit
alit
y (S
F-3
6)
Bo
dily
 Pa
in 
(SF
-36
)
Ge
ne
ral
 He
alth
 (SF
-36
)
0
30
60
90
120
p=0.48
p=0.81
p=0.11
p=0.85
p=0.83
p=0.997
p=0.33
p=0.72
All comparisons were non-significant with a Bonferroni correction (all ps > .0038)
p=0.72
p=0.83
M
ea
n 
sc
or
e
Device advisory (letter)
Device advisory (ad-hoc)
A
B
Figure 1 (A) Psychological distress and (B) health status strati-
fied by device advisory notification mode. All comparisons were
non-significant with a Bonferroni correction (all P values
.0.0038).
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Concurrent with other studies, these results indicate that ICD
patients are generally able to cope with a device advisory.8,12–
14,16 Patients may implicitly accept that with increased complexity
of technology to manage heart disease there is a trade-off with
respect to the risk of complications and hardware malfunctioning.
The downloading of the LIA software, which was applicable to all
patients with an advice notification in the current study, might also
have helped to reinstate patient confidence in the device.30
It was somewhat surprising that the mode of notification about
the device advisory had no influence on patient well-being and
health status in our study. A priori, we would have expected
that patients receiving a letter calling them in for an urgent clinical
follow-up visit would more likely be in a state of panic and there-
fore experience more distress than patients being informed about
the advisory in a more gentle way during a subsequent clinical
follow-up visit. It is possible, however, that the mode of debriefing
patients about the device advisory may be of less importance than
the source of the information (e.g. physician, manufacturer, news
media, etc.), which information is provided, and whether patients
have the possibility to attend psychological counselling, as reported
in some studies.11,12 In the current study, the notification about the
device advisory was communicated by physicians. Previously, it has
been suggested that patients prefer to learn about a device
advisory from their physician rather than from the media.31
However, the latter study used vignettes and asked patients to
rate their concerns with respect to a hypothetical rather than a
real device advisory. A more recent study examining the influence
of the source of information on patient worry levels showed no
overall difference between patients who heard about the advisory
from news media and those who heard about the advisory from a
physician, industry, or others.30 Given the absence of large-scale
well-designed studies, it is too premature to draw any firm con-
clusions about the influence of mode and source of information
about the device advisory on patient well-being.
Currently, the Heart Rhythm Society has provided recommen-
dations to the industry and physicians with respect to monitoring
device performance and how to handle device malfunctioning.5
Patient recommendations on how to deal with a device advisory
notification both at an emotional and at a behavioural level are
also available.32 In addition, information on device performance
is required to be included in the National Cardiovascular Data
Registry (NCDR) ICD Registry in the USA.5 All these initiatives
are of major importance in monitoring device performance and
obtaining a true picture of the incidence of hardware malfunc-
tioning and the concomitant risk to patient health. However,
given that neither the recommendations from the Heart
Rhythm Society nor those from the NCDR ICD Registry
include PROs—that is, asking patients to rate the impact of hard-
ware malfunctioning and device advisories on their well-being
and quality of life—the risk that the patient is still ‘left behind’
is prominent, as posited in an editorial to the Sprint Fidelis advi-
sory:6 ‘However, in 2008 the important core issues regarding
device reliability remain unsolved and longstanding issues regard-
ing patient information and patient well-being are even more
acute.’ The inclusion of routine and serial assessments of PROs
in national registries such as the NCDR ICD Registry would
enable us to track information on how device advisories affect
patient well-being, rather than relying on information from single-
center and smaller-scale ad hoc studies.8
The results of the current study should be interpreted with
some caution. First, we used a convenience sample as a non-
advisory control group. Secondly, as in previous studies examining
the impact of a device advisory notification on patients,11,12,14
there was a time interval from the notification to patient com-
pletion of the PRO measures. It is possible that the advisory noti-
fication may have an impact on patient well-being and quality of life
of patients just after the notification, but also that the impact of the
advisory dissipates over time, reflecting that patients are able to
adapt even short-term. Based on the design of our study, we are
not able to deduce whether a short-term effect was present.
Thirdly, we did not evaluate patient perception of the risk of
having a recalled Sprint Fidelis lead, which could potentially serve
as a confounder on PROs. This dimension would be interesting
to add to future studies on device advisory notifications, although
it may not be patient perception of risk per se that influences
PROs but rather whether this knowledge instills fear in and
bothers patients. Fourthly, the device advisory patients differed
from the non-advisory patients on time since first ICD implant,
with controls having had their ICD for a longer period of time.
Time since first ICD implant may serve as a potential confounder
on the results, although several studies do not support an influence
of duration since implantation on PROs.17,33 Fifthly, the control
cohort was predominantly secondary prevention patients,17 with
the potential that indication might have confounded the results.
However, based on the current literature on the impact of indi-
cation on PROs, there is no evidence to support this notion,
with available studies showing no differences in PROs between
primary and secondary prevention patients.34
This study also has several advantages. First, to our knowledge, it
is the largest study to date to examine the impact of a device advi-
sory notification on patient well-being, except for the recently
published study by Keren et al.16 Secondly, we included a broad
spectrum of PROs tapping into patient distress and health status
with the use of both disease-specific and generic measures.
Disease-specific measures are generally more sensitive to tap
symptoms that are relevant to patients and therefore less prone
to floor and ceiling effects that may obscure results.35
Conclusion
In conclusion, the mode used to inform ICD patients about the
Sprint Fidelis lead advisory was not associated with psychological
well-being and health status, as patients informed about the advi-
sory by letter calling them in for an urgent clinical follow-up visit
did not differ in psychological distress and health status from
patients informed ad hoc during a routine clinical visit. We also
found no evidence that the well-being and health status of
device advisory patients is impaired as compared to patients
without an advisory notice. Taken together, these results indicate
that ICD patients are generally able to cope with a device advisory.
Nevertheless, the arrhythmia community should consider the
advantages of including routine and serial assessments of PROs
in national registries in order to enhance our knowledge of the
impact of device advisories on patient well-being. If this is
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implemented as standard practice, with assessments available from
the time of implantation, we would not only have a pre-advisory
assessment but also be able to track patient well-being following
the advisory over time, and hence to draw more firm conclusions
about the impact on patients. For the future management and care
of ICD patients, such information would be of paramount impor-
tance given that ICD lead failures are likely to be here to stay.
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